Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...

Relmada has acquired complete ownership rights to Sepranolone, developed for Tourette syndrome (TS) from Asarina Pharma.

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an acquisition, study results ...

Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...

CORAL GABLES, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the acquisition of ...

Relmada Therapeutics has expressed its commitment to closely monitoring the bid price during the Compliance Period and taking necessary actions to meet Nasdaq’s listing requirements ...

Relmada Therapeutics (NASDAQ:RLMD), Inc., a pharmaceutical company currently trading at $0.39 and showing a significant 89% decline over the past year according to InvestingPro data, has been alerted ...